Tesamorelin 2mg

Description

Tesamorelin 2mg

Tesamorelin acetate, a synthetic peptide comprising 44 Amino acids, is analogous to the growth hormone-releasing hormone (GHRH) in structure and function both. As Tesamorelin mimics the action of a naturally occurring endogenous hormone, it also acts on specific target sites. Hence, the mechanism of action followed by Tesamorelin is very specific. Tesamorelin binds to the growth hormone-releasing hormone receptors (GHRHr) located in the anterior pituitary gland. This binding stimulates the somatotrophic cells in the pituitary gland to synthesize and secrete growth hormone (GH).  Growth hormone (GH) acts primarily on adipocytes (fat cells), hepatocytes (liver cells), myocytes (muscle cells), and osteoblasts (bone cells).  To ensure the Tesamorelin-induced release of growth hormone (GH) is within set limits, a negative feedback mechanism is initiated, so that serum growth hormone (GH) levels don’t overshoot. As Tesamorelin triggers the release of growth hormone (GH) naturally, it maintains homeostatic coordination between Hypothalamus and pituitary gland.

The primary purpose of Tesamorelin is to increase the serum levels of growth hormone (GH). The other potential benefits of the Tesamorelin therapy just come organically with it. One of the major symptoms of HIV and antiretroviral medication is lipodystrophy. It refers to either excessive build-up of fat in certain areas of the body, especially the abdominal region, or loss of normal body fat. Clinical trials have shown a considerable reduction of visceral adipose tissue (VAT) in patients suffering from HIV-associated lipodystrophy. Besides, Tesamorelin also improved body composition measures by proving effective in reducing trunk fat, waist circumference, and waist-to-hip ratio. Tesamorelin is also seen to reduce the size of carotid-intima media size (cIMT). Hence, it reduces the progression of carotid atherosclerotic vascular disease. These prospective benefits might help establish a link between Tesamorelin therapy and reduced risk of developing cardiovascular diseases. Patients with lipodystrophy have lower serum levels of Insulin-like growth factor 1 (IGF-1). Tesamorelin triggers the production (IGF-1) from the hepatocytes. IGF-7, without altering blood glucose levels, carries out the process of growth and inhibits the programmed cell death mechanism. Tesamorelin reduces the levels of cholesterol and triglycerides by carrying out the process of lipolysis. Hence, lipid profiles improved.

THIS PRODUCT IS INTENDED FOR RESEARCH ONLY. This designation allows the use of research peptides strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product is NOT for human use and can be harmful if ingested. This product is for research/laboratory use only. This product is NOT in a sterile solution and is NOT to be injected. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and should not be misbranded, misused or mislabeled as a drug, food or cosmetic.